insights_auto
为什么 CMPS 上涨了 3.35%?
深入探索chevron_right
CMPS:NASDAQ
Compass Pathways PLC
US$11.11
arrow_upward
+3.35%(+0.36) 1 天
US$11.08
arrow_downward
-0.29% (-0.032)bedtime盘后交易
休市： 10月19日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 CMPS 生成关键数据洞见…
开盘价
US$10.87
最高价
US$11.17
最低价
US$10.81
市值
15.38亿
平均成交量
294.07万
成交量
327.68万
52 周最高价
US$15.87
52 周最低价
US$4.88
每股收益
-US$3.47
Beta 版
2.55
流通股数
1.38亿
员工人数
156
开盘价
US$10.87
最高价
US$11.17
最低价
US$10.81
市值
15.38亿
平均成交量
294.07万
成交量
327.68万
52 周最高价
US$15.87
52 周最低价
US$4.88
每股收益
-US$3.47
Beta 版
2.55
流通股数
1.38亿
员工人数
156
新闻报道
来自网络来源和新闻合作伙伴
Traders Union
·
11小时前
Mark Minervini：第四季度和中期选举后的时期显示出 S&P 500 强劲的看涨季节性
www.tmgm.com
·
15小时前
美联储加息担忧缓解，道琼斯指数期货在科技巨头财报公布前上涨
TradingKey
·
1天前
标普500指数预测：摩根士丹利称美股回调接近尾声，重点关注7500点
资料
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
Compass Pathways PLC简介